Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma

Thyroid

Volumn 22, Issue 7, 2012, Pages 709-716

  Penna Martinez, Marissa ^a   Ramos Lopez, Elizabeth ^a   Stern, Julienne ^a   Kahles, Heinrich ^a   Hinsch, Nora ^b   Hansmann, Martin Leo ^b   Selkinski, Ivan ^b   Grünwald, Frank ^b   Vorländer, Christian ^c   Bechstein, Wolf O ^b   Zeuzem, Stefan ^a   Holzer, Katharina ^b   Badenhoop, Klaus ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Bürgerhospital Frankfurt ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 HYDROXYVITAMIN D; 25 HYDROXYLASE; 25 HYDROXYVITAMIN D 1ALPHA HYDROXYLASE; 25 HYDROXYVITAMIN D 24 HYDROLASE; CALCIFEDIOL; HYDROLASE; OXYGENASE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; VITAMIN BLOOD LEVEL;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADENOCARCINOMA, FOLLICULAR; ADULT; CALCIFEDIOL; CALCITRIOL; CARCINOMA; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CHOLESTANETRIOL 26-MONOOXYGENASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; STEROID HYDROXYLASES; THYROID NEOPLASMS; VITAMIN D;

EID: 84863473399     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0330     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D 2011 Global cancer statistics. CA Cancer J Clin 61:69-90.
2. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS 2011 Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 21:125-134.
3. Grant WB 2007 An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer 120:1123-1128.
4. Penna-Martinez M, Ramos-Lopez E, Stern J, Hinsch N, Hansmann ML, Selkinski I, Grünwald F, Vorländer C, Wahl RA, Bechstein WO, Zeuzem S, Holzer K, Badenhoop K 2009 Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid 19:623-628.
5. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW 2004 Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 101:7711-7715.
6. Zehnder D, Bland R, Walker EA, Bradwell AR, Howie AJ, Hewison M, Stewart PM 1999 Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol 10:2465-2473.
7. Barreto AM, Schwartz GG, Woodruff R, Cramer SD 2000 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9:265-270.
8. Miller GJ, Stapleton GE, Ferrara JA, Scott Lucia M, Pfister S, Hedlund TE, Upadhya 1992 The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 52:515-520.
9. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM 1992 Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774.
10. Sakaki T, Sawada N, Nonaka Y, Ohyama Y, Inouye K 1999 Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 CYP24 can convert 1a,25-dihydroxyvitamin D3 to calcitroic acid. Eur J Biochem 262:43-48.
11. Miller SA, Dykes DD, Polesky HF 1988 A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
12. Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K 2007 CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev 23:631-636.
13. Bailey R, Cooper JD, Zeitels L, Smyth DJ, Yang JH, Walker NM, Hyppönen E, Dunger DB, Ramos-Lopez E, Badenhoop K, Nejentsev S, Todd JA 2007 Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes. 56:2616-2621.
14. Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, Wallace C, Greissl C, Ramos-Lopez E, Hypponen E, Dunger DB, Spector TD, Ouwehand WH, Wang TJ, Badenhoop K, Todd JA 2011 Inherited variation in vitamin d genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 60:1624-1631.
15. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR 2006 Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57:234-240.
16. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, De Waziers I 2007 Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17:731-742.
17. Hewison M 2010 Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol 321:103-111.
18. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, Handunnetthi L, Handel AE, Disanto G, Orton SM, Watson CT, Morahan JM, Giovannoni G, Ponting CP, Ebers GC, Knight JC 2010 A ChIP-seq defined genomewide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res 20:1352-1360.
19. Davis CD, Milner JA 2011 Nutrigenomics, vitamin D and cancer prevention. J Nutrigenet Nutrigenomics 4:1-11.
20. Jenab M, McKay J, Bueno-de-Mesquita HB, van Duijnhoven FJ, Ferrari P, Slimani N, Jansen EH, Pischon T, Rinaldi S, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Engel P, Kaaks R, Linseisen J, Boeing H, Fisher E, Trichopoulou A, Dilis V, Oustoglou E, Berrino F, Vineis P, Mattiello A, Masala G, Tumino R, Vrieling A, van Gils CH, Peeters PH, Brustad M, Lund E, Chirlaque MD, Barricarte A, Suárez LR, Molina E, Dorronsoro M, Sala N, Hallmans G, Palmqvist R, Roddam A, Key TJ, Khaw KT, Bingham S, Boffetta P, Autier P, Byrnes G, Norat T, Riboli E 2009 Vitamin D receptor and calcium sensing receptor polymorphisms and the risk of colorectal cancer in European populations. Cancer Epidemiol Biomarkers Prev 18:2485-2491.
21. McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, Barricarte A, Berg CD, Bergland G, Bingham S, Brustad M, Bueno-de-Mesquita HB, Burdette L, Buring J, Calle EE, Chanock SJ, Clavel-Chapelon F, Cox DG, Dossus L, Feigelson HS, Haiman CA, Hankinson SE, Hoover RN, Hunter DJ, Husing A, Kaaks R, Kolonel LN, Le Marchand L, Linseisen J, McCarty CA, Overvad K, Panico S, Purdue MP, Stram DO, Stevens VL, Trichopoulos D, Willett WC, Yuenger J, Thun MJ 2009 Vitamin D receptor polymorphisms and breast cancer risk: Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 18:297-305.
22. Hawkins GA, Cramer SD, Zheng SL, Isaacs SD, Wiley KE, Chang BL, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J 2002 Sequence variants in the human 25-hydroxyvitamin D3 1-Alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate 53:175-178.
23. McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, Bostick RM, Thun MJ, Calle EE 2007 Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: A nested case-control study. Breast Cancer Res 9:R9.
24. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U 2007 Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 16:1990-1999.
25. Dong LM, Ulrich CM, Hsu L, Duggan DJ, Benitez DS, White E, Slattery ML, Farin FM, Makar KW, Carlson CS, Caan BJ, Potter JD, Peters U 2009 Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol Biomarkers Prev 18:2540-2548.
26. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, Thompson IM, Leach RJ 2009 Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 18:1869-1880.
27. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL 2009 Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 18:1929-1933.
28. Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, Abnet CC, Huang WY, Kibel AS, Crawford ED, Weinstein SJ, Chanock SJ, Schatzkin A, Hayes RB 2009 Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30:769-776.
29. Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z,Ostrander EA, Peters U, Stanford JL 2010 Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 70: 1448-1460.
30. Vaisanen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C 2005 Spatio-Temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1a,25-Dihydroxyvitamin D3. J Mol Biol 350:65-77.
31. Roff A, Wilson RT 2008 A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J Steroid Biochem Mol Biol 112:47-54.
32. Khadzkou K, Buchwald P, Westin G, Dralle H, Akerstrom G, Hellman P 2006 25-hydroxyvitamin D3 1a-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem 54:355-361.
33. Balla B, Kosa JP, Tobias B, Halaszlaki C, Takacs I, Horvath H, Speer G, Nagy Z, Horanyi J, Jaray B, Szekely E, Lakatos P 2011 Marked increase in CYP24A1 gene expression in human papillary thyroid cancer. Thyroid 21:459-460.
34. Sharma V, Fretwell D, Crees Z, Kerege A, Klopper JP 2010 Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism.Thyroid 20:1103-1111.
35. Stepien T, Krupinski R, Sopinski J, Kuzdak K, Komorowski J, Lawnicka H, Stepien H 2010 Decreased 1-25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res 41:190-194.
36. Clinckspoor I, Verlinden L, Overbergh L, Korch C, Bouillon R, Mathieu C, Verstuyf A, Decallonne B 2011 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. J Steroid Biochem Mol Biol 124:1-9.